Potential health benefits and safety considerations regarding human consumption of tea seed oil and olive oil

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20150314002

Enrollment

Unknown

Registered

2015-03-14

Start date

2015-08-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

For showing the human health value of tea seed oil and olive oil in healthy volunteers

Interventions

cooking oil,cooking oil

Experimental Dietary Supplement,Experimental Dietary Supplement

olive oil,tea seed oil

Eligibility

Sex/Gender

Male

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: a) Healthy nonsmoking, non-alcohol consuming male aged 18-45 years old. b) Body mass index (BMI) within 18-25 kg/m2. c) Four weeks before screening for study entry, volunteers will withdraw from any drugs that may affect the blood lipid level. d) Volunteers who are in good health on basis of medical history and physical examination. e) Volunteers who understand the study method, and sign the consent form, willing to comply with the study protocol. f) Volunteers with normal lipid profiles and hematological, liver or kidney functions as evaluated by routine blood tests, including complete blood count (CBC), blood urea nitrogen (BUN), creatinine (Cr), fasting blood sugar (FBS) and liver function test (LFT).

Exclusion criteria

Exclusion criteria: a) Volunteers with a history of bleeding disorders or glucose-6-phosphate dehydrogenase deficiency or thalassemia. b) Volunteers with dyslipidemia (total cholesterol (TC) â‰¥ 240 mg/dL; low-density lipoprotein cholesterol (LDL-C) â‰¥ 160 mg/dL; triacylglycerol (TAG) â‰¥ 200 mg/dL). c) Volunteers who take drugs affecting the blood lipid level four weeks before enrollment in the study. d) Volunteers who have other medical conditions, which in the opinion of the investigators, put the volunteers at risk participating the study.

Design outcomes

Primary

Measure	Time frame
Plasma lipid profiles on Day 0, 15 and Day 22 of each Study Period TC, LDL-C, TAG, and HDL-C level	—

Secondary

Measure	Time frame
Obesity induction on Day 0, 15 and Day 22 of each Study Period ALT, AST, ALP, TB, DB, total protein, albumin, globulin,Safety profiles on Day 0, 15 and Day 22 of each Study Period Vital signs, Liver function test, Renal function test, CBC,Antioxidant activity on Day 0, 15 and Day 22 of each Study Period Malondialdehyde concentration,Plasma polyphenol concentration on Day 0, 15 and Day 22 of each Study Period HPLC	—

Measure

Time frame

Obesity induction on Day 0, 15 and Day 22 of each Study Period ALT, AST, ALP, TB, DB, total protein, albumin, globulin,Safety profiles on Day 0, 15 and Day 22 of each Study Period Vital signs, Liver function test, Renal function test, CBC,Antioxidant activity on Day 0, 15 and Day 22 of each Study Period Malondialdehyde concentration,Plasma polyphenol concentration on Day 0, 15 and Day 22 of each Study Period HPLC

—

Countries

THAILAND

Contacts

Public ContactNuchanart Suealek

Faculty of Medicine, Thammasat University

sunuchan@tu.ac.th086-6582414

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026